Efficacy and Safety of Bupivacaine Combined with Bupivacaine Liposome in Serratus Anterior Plane Block for Postoperative Analgesia after Open Hepatectomy: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500109293

Enrollment

Unknown

Registered

2025-09-16

Start date

2025-10-01

Completion date

Unknown

Last updated

2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia for open hepatectomy surgery

Interventions

Experimental group :Ultrasound-guided serratus anterior plane block at the 7th rib level: Inject a mixture of bupivacaine and bupivacaine liposome into the deep surface of the serratus anterior muscle

Control group:Ultrasound-guided serratus anterior plane block at the 7th rib level: Inject 30 mL of 0.25% bupivacaine hydrochloride into the deep surface of the serratus anterior muscle ( between the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age: 18-65 years; 2. ASA classification: I-III; 3. BMI: 18.5 <= BMI < 28 kg/m^2; 4. Scheduled for open partial hepatectomy; 5. The patient agrees to participate in the study and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Allergy to amide local anesthetics; 2. Infection at the puncture site; 3. Patients with mental disorders or unable to cooperate; 4. History of chronic opioid use (defined as continuous use for more than 3 months or a daily morphine equivalent greater than 5mg/d for more than 1 month).

Design outcomes

Primary

Measure	Time frame
Mean NRS pain score at rest across 6 time points within 48 hours after surgery;	—

Secondary

Measure	Time frame
Intraoperative opioid dosage;Postoperative opioid dosage within 48 hours;Usage of non-opioid analgesics within 48 hours after surgery;Number of intravenous patient-controlled analgesia pump presses within 48 hours after surgery;Number of effective presses of intravenous patient-controlled analgesia pump within 48 hours after surgery;Incidence of opioid-related adverse reactions within 48 hours after surgery;Time to first ambulation after surgery;Time to first flatus after surgery;Time to first oral intake after surgery;Nerve block-related complications;Satisfaction with pain control;QoR-15 Recovery Quality Score;	—

Measure

Time frame

Intraoperative opioid dosage;Postoperative opioid dosage within 48 hours;Usage of non-opioid analgesics within 48 hours after surgery;Number of intravenous patient-controlled analgesia pump presses within 48 hours after surgery;Number of effective presses of intravenous patient-controlled analgesia pump within 48 hours after surgery;Incidence of opioid-related adverse reactions within 48 hours after surgery;Time to first ambulation after surgery;Time to first flatus after surgery;Time to first oral intake after surgery;Nerve block-related complications;Satisfaction with pain control;QoR-15 Recovery Quality Score;

—

Countries

China

Contacts

Public ContactGe Shengjin

Zhongshan Hospital, Fudan University

ge.shengjin@zs-hospital.sh.cn+86 136 0192 6171

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026